About the Authors

Scott G Filler

To whom correspondence should be addressed. E-mail: sfiller@ucla.edu

Donald C Sheppard

Competing Interests

Scott G. Filler has equity in Novadigm Therapeutics, a company that is developing a vaccine against C. albicans.

Author Contributions

SGF and DCS wrote the paper.